#Clinical Trials #Heart Failure #Relief Cardiovascular

Relief Cardiovascular Secures $12M in Series A Funding

On January 8, 2025, Relief Cardiovascular, a company under the inQB8 Medical Technologies umbrella, announced it has completed a significant $12 million Series A financing. This funding round was spearheaded by esteemed organizations including Broadview Ventures and Advent Life Sciences, with additional participation from Pacific Health Investment, Heartwork Capital, among others.

The capital raised is earmarked for advancing the product development of the Relief System, a novel transcatheter smart implant that is set to revolutionize the management of heart failure. The primary goal is to conduct a first-in-human feasibility study focused on assessing the device's safety and efficacy. This next step is crucial for demonstrating the potential benefits of the Relief System in clinical settings.

Innovative Approach to Heart Failure Treatment

The Relief System is designed to monitor and modulate renal vein pressures—a groundbreaking approach to fluid management in patients suffering from heart failure. Heart failure remains a pressing issue in healthcare, burdening patients and systems alike. The innovative design of the Relief System aims to fill a significant gap in existing treatment modalities.

Dr. Maria Berkman, Head of Medtech at Broadview Ventures, expressed optimism about the Relief System, stating, “This device addresses a critical gap in patient care.” Her sentiments were echoed by Dr. Shahzad Malik from Advent Life Sciences, who pointed out that the relief device offers hope to patients with diuretic-resistant heart failure.

The technology operates through a transcatheter implant that employs a unique